Drug release device and endoscopic assembly

Abstract

The present application relates to the technical field of endoscopes. Disclosed are a drug release device and an endoscopic assembly. The drug release device comprises a first tube, a balloon and a light-emitting structure. The balloon is configured as a light-transmissive and expandable structure, and a structural layer of the balloon encloses an inner cavity, such that the inner cavity and the distal end of the first tube are sealed and are in communication with each other. Moreover, the first tube extends into the inner cavity, and then the light-emitting structure is provided in the balloon. Light emitted by the light-emitting structure and a photosensitive cross-linked drug composite layer located outside the structural layer are used to induce a cross-linking reaction. After the balloon is inserted into the uterus, a liquid can be injected into the balloon through the first tube so as to expand the balloon, and the expanded balloon can abut against the endometrium. After the light-emitting structure emits light, the photosensitive cross-linked drug composite layer can adhere to the surface of the endometrium, thereby enabling a drug contained in the photosensitive cross-linked drug composite layer to fully and tightly attach to the endometrium for the continuous treatment or repair of the endometrium.

Description

Drug delivery device and endoscope assembly Technical Field

[0001] This application relates to the field of endoscopy, and more particularly to a drug delivery device and an endoscope assembly. Background Technology

[0002] A uterine tamponade balloon is a medical device primarily used for gynecological conditions such as uterine bleeding in women. It is used to insert a balloon into the uterus and inflate it to achieve the effect of dilation and compression to stop bleeding. It can also be used to deliver medication through the balloon to the uterus to treat or repair the endometrium.

[0003] However, because the germinal layer of the endometrium is not thick enough when it is damaged, the existing uterine packing balloons cannot attach drugs to the endometrium for continuous treatment or repair of the endometrial membrane. Summary of the Invention

[0004] This application discloses a drug delivery device and an endoscope assembly to at least partially improve the above-mentioned technical problems.

[0005] To solve the above problems, this application adopts the following technical solution:

[0006] On one hand, this application provides a drug delivery device, including: a first tube, a balloon, and a light-emitting structure. The balloon is a light-transmitting and inflatable structure, having a structural layer and a photosensitive cross-linked drug composite layer. The structural layer forms an inner cavity, which is sealed to and communicates with the distal end of the first tube, with the first tube extending into the inner cavity. The light-emitting structure is located inside the balloon, and the light emitted by the light-emitting structure can induce a cross-linking reaction with the photosensitive cross-linked drug composite layer.

[0007] In one embodiment, the structural layer includes a first structural portion and a second structural portion stacked along the radial direction of the balloon, the first structural portion being connected to the second structural portion and close to the inner cavity, the photosensitive cross-linked drug composite layer being disposed on the second structural portion, and the first structural portion being configured to expand to be on the same surface as the second structural portion when the balloon is inflated.

[0008] In one embodiment, the photosensitive cross-linked drug composite layer is disposed on a portion of the second structural portion, and a first gap is present between adjacent photosensitive cross-linked drug composite layers.

[0009] In one embodiment, the photosensitive crosslinked drug composite layer includes: a photosensitive crosslinking agent, a porous carrier, and a drug, wherein the porous carrier is connected to the second structural portion, the photosensitive crosslinking agent is disposed on the peripheral sidewall of the porous carrier, and the drug is disposed on the porous carrier.

[0010] In one embodiment, there is a second gap between adjacent first structural portions, the second gap pointing to the center of the first structural portion connected to two adjacent first structural portions.

[0011] In one embodiment, the distal end of the first tube has a constricted region, the radial dimension of which is smaller than the radial dimension of the proximal end of the first tube, and the structural layer is sealed to the constricted region.

[0012] In one embodiment, the region of the first tube extending into the interior of the balloon serves as the light-emitting structure.

[0013] In one embodiment, the drug delivery device further includes a second tube disposed inside the first tube, wherein the first tube is a light-transmitting structure and the second tube serves as the light-emitting structure.

[0014] In one embodiment, the drug delivery device further includes a second tube body disposed inside the first tube body and communicating with the interior of the first tube body. Both the first tube body and the second tube body are light-transmitting structures, and the light-emitting structure is detachably disposed inside the second tube body.

[0015] On the other hand, embodiments of this application also provide an endoscope assembly, including an endoscope and a drug delivery device as described above, wherein the endoscope has an instrument channel and the drug delivery device is detachably disposed within the instrument channel.

[0016] The technical solution adopted in this application can achieve the following beneficial effects:

[0017] The drug delivery device provided in this application embodiment uses a translucent and inflatable balloon structure. The balloon's structural layers form an inner cavity, which is sealed and connected to the distal end of a first tube. The first tube extends into the inner cavity, and a light-emitting structure is placed inside the balloon. The light emitted by the light-emitting structure induces a cross-linking reaction with a photosensitive cross-linked drug composite layer located outside the structural layers. When the balloon is inserted into the uterus, liquid can be injected into the balloon through the first tube to inflate it. After inflating, the balloon can contact the endometrium. The light emitted by the light-emitting structure allows the photosensitive cross-linked drug composite layer to adhere to the surface of the endometrium, thereby ensuring that the drug within the photosensitive cross-linked drug composite layer is fully and tightly attached to the endometrium for continuous treatment or repair of the endometrial membrane. Applying the above-described drug delivery device to an endoscope assembly can also solve the aforementioned technical problems. Attached Figure Description

[0018] To more clearly illustrate the technical solutions in the embodiments of this application or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of this application. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0019] Figure 1 shows a schematic diagram of the balloon in a contracted state in an endoscope assembly according to an embodiment of this application.

[0020] Figure 2 shows a schematic diagram of the balloon in an inflated state in an endoscope assembly according to an embodiment of this application.

[0021] Figure 3 shows a schematic diagram of the structure of an endoscope assembly in an embodiment of this application, in which the balloon is in a contracted state after being inserted into the uterus.

[0022] Figure 4 shows a schematic diagram of the structure of an endoscope assembly in an inflated state after being inserted into the uterus according to an embodiment of this application.

[0023] Figure 5 is an enlarged view of point A in Figure 1.

[0024] Figure 6 is an enlarged view of point B in Figure 2.

[0025] Figure 7 shows a cross-sectional view of a partial structure of an endoscope assembly according to an embodiment of this application.

[0026] Figure 8 shows a partial structural schematic diagram of the balloon in the contracted state of a drug delivery device according to an embodiment of this application.

[0027] Figure 9 shows a schematic diagram of the structure of a balloon in an inflated state and in contact with the endometrium in a drug delivery device according to an embodiment of this application.

[0028] In the diagram: 1. Endoscope assembly; 10. Drug delivery device; 110. First tube; 111. Narrowing area; 120. Balloon; 121. Structural layer; 1211. First structural part; 1212. Second structural part; 1213. First gap; 1214. Second gap; 122. Photosensitive cross-linked drug composite layer; 1221. Photosensitive cross-linking agent; 1222. Porous carrier; 123. Lumen; 130. Light-emitting structure; 140. Second tube; 20. Endoscope; 210. Instrument channel; 220. Injection channel; 2. Uterus. Detailed Implementation

[0029] To make the objectives, technical solutions, and advantages of this application clearer, the technical solutions of this application will be described in detail below. Obviously, the described embodiments are merely some embodiments of this application, and not all embodiments. Based on the embodiments in this application, all other implementation methods obtained by those skilled in the art without creative effort are within the scope of protection of this application.

[0030] The terms "first," "second," etc., used in the specification and claims of this application are used to distinguish similar objects and not to describe a specific order or sequence. It should be understood that such use of data can be interchanged where appropriate so that embodiments of this application can be implemented in orders other than those illustrated or described herein, and the objects distinguished by "first," "second," etc., are generally of the same class and the number of objects is not limited; for example, a first object can be one or more. Furthermore, in the specification and claims, "and / or" indicates at least one of the connected objects, and the character " / " generally indicates that the preceding and following objects are in an "or" relationship.

[0031] In the various embodiments of this application, "near end" and "far end" refer to the distance of each component from the user in the usage environment. The end closer to the user is designated as the "near end", and the end farther from the user is designated as the "far end".

[0032] The inventive concept of this application is described here:

[0033] A uterine tamponade balloon is a medical device primarily used for gynecological conditions such as uterine bleeding in women. It is used to insert a balloon into the uterus and inflate it to achieve the effect of dilation and compression to stop bleeding. It can also be used to deliver medication through the balloon to the uterus to treat or repair the endometrium.

[0034] However, because the germinal layer of the endometrium is not thick enough when it is damaged, the existing uterine packing balloons cannot attach drugs to the endometrium for continuous treatment or repair of the endometrial membrane. If a targeted injection method is used, although this can ensure that the drug can fully contact the endometrium, this method has a small range of action and is very complicated to operate.

[0035] Based on this, the inventors have provided a drug delivery device and an endoscope assembly. The drug delivery device can use a photosensitive cross-linking reaction to tightly adhere a drug-carrying carrier to the endometrium, thus enabling large-area drug delivery to the endometrium and is easy to operate.

[0036] The following detailed description of an endoscope assembly 1 and an endoscope 20 provided in this application, with reference to Figures 1 to 9, through specific embodiments and application scenarios, will be provided in detail.

[0037] Please refer to Figures 1-4 simultaneously. This application embodiment provides an endoscope assembly 1, which can be used to apply medication to the endometrium for continuous treatment or repair of the endometrium. The endoscope assembly 1 may include an endoscope 20 and a drug delivery device 10, wherein the endoscope 20 serves as a carrier for the drug delivery device 10. The drug delivery device 10 is inserted into the uterus 2 through the endoscope 20, and the drug delivery device 10 is used to attach medication to the endometrium.

[0038] Please refer to Figures 5 and 6 simultaneously. The endoscope 20 may have an instrument channel 210 and an injection channel 220. The instrument channel 210 can be used to accommodate the drug delivery device 10, and the injection channel 220 can communicate with the drug delivery device 10. In this embodiment, the drug delivery device 10 is detachably disposed within the instrument channel 210 so that the endoscope 20 can be reused.

[0039] Please refer to Figures 5 and 7 simultaneously. The drug delivery device 10 may include: a first tube 110, a balloon 120, and a light-emitting structure 130. The balloon 120 may be connected to the first tube 110. The light-emitting structure 130 may be used to emit light and trigger the photosensitive crosslinking agent 1221 in the balloon 120 to induce a crosslinking reaction, so that the balloon 120 can have adhesive properties. Thus, when the balloon 120 comes into contact with the endometrium, it can adhere the drug to the endometrium.

[0040] Specifically, the first tube 110 can be connected to the injection channel 220. The first tube 110 can be used to inject liquid into the balloon 120 to inflate the balloon 120. This embodiment does not limit the liquid used; for example, in some embodiments, it can be saline solution. The balloon 120 can be connected to the distal end of the first tube 110 and sealed to the distal end of the first tube 110. In this embodiment, the balloon 120 can be configured to be light-transmitting and inflatable.

[0041] In one embodiment, the distal end of the first tube 110 may have a constricted region 111, the radial dimension of which may be smaller than the radial dimension of the proximal end of the first tube 110. The balloon 120 may be connected to the constricted region 111, which makes the dimensions of the entire drug delivery device 10 more uniform and avoids the distal end of the drug delivery device 10 becoming larger after being connected to the balloon 120, making it difficult to move smoothly within the device channel 210.

[0042] Please refer to Figures 8 and 9 simultaneously. The balloon 120 may have a structural layer 121 and a photosensitive cross-linked drug composite layer 122. The structural layer 121 may form an inner cavity 123. The first tube 110 may extend into the inner cavity 123. It is understood that since the balloon 120 has low structural strength and is prone to collapse when it is in a contracted state, extending the first tube 110 into the inner cavity 123 can make the first tube 110 serve as a supporting structure for the balloon 120. This facilitates the delivery of the drug delivery device 10 into the uterus 2. At the same time, the first tube 110 can also play a guiding role during the delivery of the device into the uterus 2.

[0043] In one specific embodiment, the photosensitive crosslinked drug composite layer 122 may include: a photosensitive crosslinking agent 1221, a porous carrier 1222, and a drug. The porous carrier 1222 can be used to carry the drug. This application does not limit the specific form of the porous carrier 1222. For example, in one embodiment, the porous carrier 1222 can be an inorganic carrier, such as silica or aluminum hydroxide. In another embodiment, the porous carrier 1222 can also be an organic carrier, such as polyester, polyamide, polyorthoester, polyoxyethylene, or polyamide ester. The specific form can be determined according to actual conditions. The photosensitive crosslinking agent 1221 can be disposed on the peripheral sidewall of the porous carrier 1222. The photosensitive crosslinking agent 1221 can interact with the light emitted by the light-emitting structure 130 and induce a crosslinking reaction, thereby allowing the porous carrier 1222 to adhere to the endometrium, thus enabling the drug to fully contact the endometrium. The embodiments of this application do not limit the specific form of the drug, such as platelet-rich plasma (PRP).

[0044] Referring specifically to Figure 8, the structural layer 121 may include a first structural portion 1211 and a second structural portion 1212 stacked along the radial direction of the balloon 120. The first structural portion 1211 may be connected to the second structural portion 1212, and the first structural portion 1211 is closer to the inner cavity 123 than the second structural portion 1212. The photosensitive crosslinked drug composite layer 122 may be disposed on the second structural portion 1212. That is, in this embodiment, the photosensitive crosslinked drug composite layer 122 may be located on the outer surface of the balloon 120, and the structural layer 121 may be located on the inner surface of the balloon 120. The first structural portion 1211 may be configured to expand to be on the same surface as the second structural portion 1212 after inflation.

[0045] Furthermore, in one embodiment, the photosensitive crosslinked drug composite layer 122 is disposed in a portion of the second structural portion 1212. Specifically, the porous carrier 1222 can be disposed in a portion of the second structural portion 1212, such that a first gap 1213 exists between adjacent photosensitive crosslinked drug composite layers 122. It is understood that since the photosensitive crosslinked drug composite layer 122 is typically opaque, providing a first gap 1213 between adjacent photosensitive crosslinked drug composite layers 122 facilitates the induction of a crosslinking reaction between the light emitted by the light-emitting structure 130 and the photosensitive crosslinking agent 1221 in the photosensitive crosslinked drug composite layer 122.

[0046] In one embodiment, a second gap 1214 may be present between adjacent first structural portions 1211, the second gap 1214 pointing towards the center of the first structural portion 1211 connected to the two adjacent first structural portions 1211. That is, in this embodiment, when the first structural portion 1211 unfolds, the second structural portion 1212 can be subjected to more uniform force, avoiding the collapse of a part of the second structural portion 1212 during the unfolding process of the first structural portion 1211, which would cause the porous carrier 1222 on the second structural portion 1212 to loosen and fall off.

[0047] This application does not limit the specific location and form of the light-emitting structure 130. For example, in one embodiment, the region of the first tube 110 extending into the balloon 120 can serve as the light-emitting structure 130. In a preferred embodiment, the first tube 110 can also be configured as a light-transmitting structure, which further facilitates the crosslinking reaction of the photosensitive crosslinking agent 1221.

[0048] In another embodiment, the drug delivery device 10 may also include a second tube 140, which may be disposed inside the first tube 110. The second tube 140 may serve as a light-emitting structure 130, and in this embodiment, the first tube 110 is also a light-transmitting structure. It is understood that the embodiments of this application do not limit the connection method between the second tube 140 and the first tube 110. For example, it may be integrally formed, or it may be slidably connected and detachably connected. The specific configuration can be made according to the actual situation.

[0049] For example, in another embodiment, the drug delivery device 10 may also include a second tube 140, which may also be disposed inside the first tube 110. However, in this embodiment, the second tube 140 is used only as a conduit, and the light-emitting structure 130 is detachably disposed within the second tube 140. It is understood that since the first tube 110 is needed to inject liquid into the lumen 123 of the balloon 120, separately disposing of the light-emitting structure 130 within the second tube 140 avoids interference from the liquid on the light-emitting structure 130.

[0050] In other embodiments, the light-emitting structure 130 may also be disposed between the structural layer 121 and the photosensitive crosslinking drug composite layer 122. This allows the light-emitting structure 130 to be closer to the photosensitive crosslinking agent 1221, thereby improving the efficiency of the crosslinking reaction of the photosensitive crosslinking agent 1221. The specific placement of the light-emitting structure 130 can be determined according to the actual situation.

[0051] The drug delivery device 10 provided in this application embodiment is configured with a transparent and expandable balloon 120, and the structural layer 121 of the balloon 120 surrounds an inner cavity 123. The inner cavity 123 is sealed and connected to the distal end of the first tube 110. The first tube 110 is extended into the inner cavity 123. A light-emitting structure 130 is provided inside the balloon 120. The light emitted by the light-emitting structure 130 induces a cross-linking reaction with the photosensitive cross-linked drug composite layer 122 located outside the structural layer 121. When the balloon 120 is inserted into the uterus 2, liquid can be injected into the balloon 120 through the first tube 110 to inflate the balloon 120. After the balloon 120 is inflated, it can come into contact with the endometrium. After the light-emitting structure 130 emits light, the photosensitive cross-linked drug composite layer 122 can adhere to the surface of the endometrium. This allows the drug in the photosensitive cross-linked drug composite layer 122 to fully and tightly adhere to the endometrium for continuous treatment or repair of the endometrial membrane. Applying the aforementioned drug delivery device 10 to the endoscope assembly 1 can also solve the above-mentioned technical problems.

[0052] It should be noted that, in this document, the terms "comprising," "including," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements includes not only those elements but also other elements not expressly listed, or elements inherent to such a process, method, article, or apparatus. Unless otherwise specified, an element defined by the phrase "comprising one..." does not exclude the presence of other identical elements in the process, method, article, or apparatus that includes that element.

[0053] Furthermore, it should be noted that the scope of the methods and apparatus in the embodiments of this application is not limited to performing functions in the order shown or discussed, but may also include performing functions substantially simultaneously or in the reverse order, depending on the functions involved. For example, the described methods may be performed in a different order than described, and various steps may be added, omitted, or combined. In addition, features described with reference to certain examples may be combined in other examples.

[0054] The above description is merely a specific embodiment of this application, but the scope of protection of this application is not limited thereto. Any changes or substitutions that can be easily conceived by those skilled in the art within the scope of the technology disclosed in this application should be included within the scope of protection of this application.

Claims

1. A drug delivery device, characterized in that, include: first tube body; A balloon, wherein the balloon is a light-transmitting and inflatable structure, the balloon has a structural layer and a photosensitive cross-linked drug composite layer, the structural layer surrounds an inner cavity, the inner cavity is sealed to the distal end of the first tube and communicates with the first tube, the first tube extends into the inner cavity; The light-emitting structure is located inside the balloon, and the light emitted by the light-emitting structure can induce a cross-linking reaction with the photosensitive cross-linked drug composite layer.

2. The drug delivery device according to claim 1, characterized in that, The structural layer includes a first structural portion and a second structural portion stacked along the radial direction of the balloon. The first structural portion is connected to the second structural portion and is close to the inner cavity. The photosensitive cross-linked drug composite layer is disposed on the second structural portion. The first structural portion is configured to expand to be on the same surface as the second structural portion when the balloon is inflated.

3. The drug delivery device according to claim 2, characterized in that, The photosensitive cross-linked drug composite layer is disposed in a portion of the second structural part, and there is a first gap between adjacent photosensitive cross-linked drug composite layers.

4. The drug delivery device according to claim 3, characterized in that, The photosensitive crosslinked drug composite layer includes: a photosensitive crosslinking agent, a porous carrier, and a drug. The porous carrier is connected to the second structural part, the photosensitive crosslinking agent is disposed on the peripheral sidewall of the porous carrier, and the drug is disposed on the porous carrier.

5. The drug delivery device according to claim 2, characterized in that, There is a second gap between adjacent first structural parts, and the second gap points to the center of the first structural part that connects to the two adjacent first structural parts.

6. The drug delivery device according to claim 1, characterized in that, The distal end of the first tube has a constricted region, the radial dimension of which is smaller than the radial dimension of the proximal end of the first tube, and the structural layer is sealed to the constricted region.

7. The drug delivery device according to any one of claims 1-5, characterized in that, The region of the first tube extending into the interior of the balloon serves as the light-emitting structure.

8. The drug delivery device according to any one of claims 1-5, characterized in that, The drug delivery device further includes a second tube body disposed inside the first tube body, wherein the first tube body is a light-transmitting structure and the second tube body serves as the light-emitting structure.

9. The drug delivery device according to any one of claims 1-5, characterized in that, The drug delivery device further includes a second tube body, which is disposed inside the first tube body and communicates with the interior of the first tube body. Both the first tube body and the second tube body are light-transmitting structures, and the light-emitting structure is detachably disposed inside the second tube body.

10. An endoscope assembly, characterized in that, The invention includes an endoscope and a drug delivery device as described in any one of claims 1-9, wherein the endoscope has an instrument channel and the drug delivery device is detachably disposed within the instrument channel.

Images